A treatment-specific marginal structural Cox model for the effect of treatment discontinuation.

articifial censoring causal inference discontinuation inverse probability weighting time-dependent confounding

Journal

Pharmaceutical statistics
ISSN: 1539-1612
Titre abrégé: Pharm Stat
Pays: England
ID NLM: 101201192

Informations de publication

Date de publication:
09 2022
Historique:
revised: 07 02 2022
received: 23 01 2021
accepted: 13 03 2022
pubmed: 1 4 2022
medline: 20 9 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Patients taking a prescribed medication often discontinue their treatment; however, this may negatively impact their health outcomes. If doctors had statistical evidence that discontinuing some prescribed medication shortened, on average, the time to a clinical event (e.g., death), they could use that knowledge to encourage their patients to stay on the prescribed treatment. We describe a treatment-specific marginal structural Cox model for estimation of the causal effect of treatment discontinuation on a survival endpoint. The effect of treatment discontinuation is quantified by the hazard ratio of the event hazard rate had the population followed the regime "take treatment

Identifiants

pubmed: 35357077
doi: 10.1002/pst.2211
pmc: PMC9481666
mid: NIHMS1799136
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

988-1004

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL079896
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES031651
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG066883
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA142538
Pays : United States

Informations de copyright

© 2022 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

Références

Europace. 2016 Aug;18(8):1150-7
pubmed: 26830891
Pharm Stat. 2022 Sep;21(5):988-1004
pubmed: 35357077
Am Heart J. 2012 Jan;163(1):13-19.e1
pubmed: 22172431
Am J Epidemiol. 2008 Sep 15;168(6):656-64
pubmed: 18682488
Lifetime Data Anal. 2007 Dec;13(4):471-80
pubmed: 17768681
Circulation. 2011 Feb 1;123(4):417-24
pubmed: 21242484
J Am Soc Nephrol. 2014 Mar;25(3):431-42
pubmed: 24385595
Avicenna J Med. 2016 Jan-Mar;6(1):8-16
pubmed: 26955600
Circulation. 2007 May 29;115(21):2689-96
pubmed: 17515465
J Epidemiol Community Health. 2006 Jul;60(7):578-86
pubmed: 16790829
J Thromb Haemost. 2008 Sep;6(9):1500-6
pubmed: 18573187
Biometrics. 2018 Sep;74(3):900-909
pubmed: 29359317
Biometrika. 2020 Mar;107(1):123-136
pubmed: 33162561
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Int J Cardiol Heart Vasc. 2018 Aug 31;20:56-62
pubmed: 30186937
Epidemiology. 2000 Sep;11(5):561-70
pubmed: 10955409

Auteurs

Dana Johnson (D)

Biostatistics, United Therapeutics Corp., Silver Spring, North Carolina, USA.

Karen Pieper (K)

Statistics, Thrombosis Research Institute, London, UK.

Shu Yang (S)

Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH